Business
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale,
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\nGeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact\n\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation, novel gene-disease discoveries, the real-world impact of earlier diagnoses, and more.\n\n\nThis research highlights the scale and clinical impact of GeneDx Infinity™ – the largest and most comprehensive rare disease genomic dataset – and GeneDx’s leadership in bringing exome and genome testing to the standard of care. The research showcases how GeneDx leverages AI, combined with world-class data and clinical expertise, to enhance variant interpretation, accelerate analysis, and scale insights from Infinity.\n\n\n“Only GeneDx can study exome and genome performance at the scale reflected in GeneDx Infinity – more than a million exomes and genomes linked to deep clinical context,” said Dr. Linda Genen, MD, MPH, Chief Medical Officer at GeneDx. “The data we’re presenting at ACMG 2026 show that when genomic testing is used earlier and interpreted with the power of real-world genomic intelligence, it doesn’t just provide answers – it fundamentally changes care. Across diverse clinical settings and provider types, exome and genome testing shorten the diagnostic journey, guide medical management, and reduce healthcare costs for patients and health systems alike.”\n\n\nGeneDx Platform Presentations:\n\n\nUtilization and Impact of Exome and Genome Sequencing by Non-Genetics Providers\nThursday, March 12 at 12 p.m. BCC Ballroom 1 – Melanie P. Napier, MSc, MSc, CGC, CCGC, GeneDx\nData from 135,000 WES/WGS tests (2022–2024) show that diagnostic yield and VUS rates were comparable between genetics and non-genetics providers, underscoring appropriate utilization and the expanding access to genomic testing.\n\n\nA Rapid, Novel Approach to Rare Disease and Clinical Gen...